[Interferon production in lymph nodes draining breast carcinoma and its augmentation by OK-432].
In breast cancer patients on whom modified radical mastectomy is performed, relatively more of the regional lymph nodes draining the breast carcinoma remain in comparison with standard radical mastectomy. Therefore, investigation of the functions of lymph nodes draining breast carcinoma has become important. Lymphocyte subsets of 33 axillary lymph nodes from 19 breast cancer patients were analysed using flow cytometry. In axillary lymph nodes, both OKT-3(+) cells and OKT-8(+) cells were decreased in comparison with those in peripheral blood. However, the OKT 4/8 ratio was increased in axillary lymph nodes. These findings suggest that axillary lymph nodes are immunologically more functional against cancer spread than peripheral blood. OK-M1(+) cells, Leu-7(+) cells and Leu-11a(+) cells were decreased in axillary lymph nodes in comparison with peripheral blood. The ability of IFN production in axillary lymph nodes and peripheral blood was analysed using the cytopathic effect of VSV-sindbis virus. After 72 hours incubation, IFN production of axillary lymph nodes showed maximum titer. When lymph nodes were co-cultured with OK-432, IFN production of axillary lymph nodes was strongly augmented. IFN production of axillary lymph nodes draining breast carcinoma were increased in comparison with peripheral blood. Axillary lymph nodes draining breast carcinoma would thus seem to be important as cytokine-producing organs. IFN has been found to be an activator of NK cells, cytotoxic T cells and IL-2 production. Axillary lymph nodes may therefore play an important role against the spread of breast cancer.
D001365:Axilla; D001688:Biological Products / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007372:Interferons / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000276:immunology; D008198:Lymph Nodes / Q000378:metabolism*; D008214:Lymphocytes / Q000145:classification / Q000276:immunology; D010844:Picibanil / Q000494:pharmacology*
D001688:Biological Products; D010844:Picibanil; D007372:Interferons